Seoul researchers tout Guardant360 clinical results

By staff writers

June 1, 2020 -- South Korean researchers highlighted clinical results from a study that used precision oncology company Guardant Health's Guardant360 test in patients with ALK-rearranged non-small cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO) annual meeting.

A team from Samsung Medical Center in Seoul found that the test offers "useful prognostic information beyond actionable biomarkers" for this patient population, Guardant said in a statement.

Results were presented in a poster presentation on May 29 at the meeting, which is being held in a virtual format this year. The study included blood samples from patients with ALK-positive advanced stage NSCLC collected before ALK-targeted treatment, two months after treatment started, and when the cancer had progressed. It found the absence of tumor-associated circulating free DNA (cfDNA) prior to and disappearance of cfDNA two months after starting treatment were both associated with both longer progression-free and overall survival, according to Guardant Health.

"Normally, we evaluate cfDNA to identify actionable biomarkers in people with advanced non-small cell lung cancer, which we could do for most patients in this study," study author Dr. Myung-Ju Ahn said in Guardant's statement. "But we also found that when we could not detect any tumor DNA in blood prior to treatment there were favorable prognostic implications for patients with ALK positive disease."

Genomic profiling uncovers treatment resistance in lung cancer patients
Comprehensive genomic profiling identified alterations that may be associated with treatment resistance in a subtype of non-small cell lung cancer in...
Survey: Molecular testing greatly underused in lung cancer patients
Molecular testing is greatly underused in patients with non-small cell lung cancer for a variety of reasons, including cost, concerns about quality, turnaround...
FDA approves Agilent assay for lung cancer
The U.S. Food and Drug Administration (FDA) has cleared Agilent Technologies' companion diagnostic assay for use in guiding immunotherapy treatment in...
FDA clears FoundationOne companion test for lung cancer drug
Foundation Medicine's FoundationOne companion diagnostic has been cleared by the U.S. Food and Drug Administration (FDA) for a new indication in guiding...
Liquid biopsy test detects biomarker for immunotherapy
Precision oncology company Guardant Health is touting a new study confirming that its Guardant360 liquid biopsy test can accurately detect microsatellite...

Copyright © 2020

Last Updated eh 6/1/2020 12:06:16 PM